EYE
MCID: RRR001
MIFTS: 55

Rere-Related Disorders (EYE)

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Rere-Related Disorders

MalaCards integrated aliases for Rere-Related Disorders:

Name: Rere-Related Disorders 25
Heart Failure 56 6 44 17
Abnormality of the Eye 30 6
Heart Diseases 56 44
Eye Diseases 56 44
Neurodevelopmental Disorder with or Without Anomalies of the Brain 25
or Heart 25
Nedbeh 25
Eye 25

Classifications:



External Ids:

Summaries for Rere-Related Disorders

MedlinePlus : 44 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Rere-Related Disorders, also known as heart failure, is related to retinal disease and stargardt disease. An important gene associated with Rere-Related Disorders is IMPG2 (Interphotoreceptor Matrix Proteoglycan 2), and among its related pathways/superpathways are Phototransduction and Visual Cycle in Retinal Rods. The drugs Dobutamine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotype is vision/eye.

GeneReviews: NBK538938

Related Diseases for Rere-Related Disorders

Diseases related to Rere-Related Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3807)
# Related Disease Score Top Affiliating Genes
1 retinal disease 31.4 ABCC6 CNGB3 IMPG2 RDH12
2 stargardt disease 31.3 CNGB3 RDH12
3 leber congenital amaurosis 31.2 CNGA3 CNGB3 RDH12
4 blue cone monochromacy 31.2 CNGA3 CNGB3
5 pathologic nystagmus 31.1 CNGA3 CNGB3
6 achromatopsia 2 30.5 CNGA3 CNGB3
7 ewing sarcoma 30.3 ABCC6 CNGA3 CNGB3 IMPG2 RDH12 VPS13B
8 achromatopsia 30.2 CNGA3 CNGB3
9 retinitis pigmentosa 56 29.5 IMPG2 RDH12
10 jalili syndrome 29.3 CNGA3 CNGB3
11 cone-rod dystrophy 6 29.2 CNGA3 CNGB3
12 retinitis pigmentosa 26 29.1 CNGA3 CNGB3
13 color blindness 29.1 CNGA3 CNGB3
14 retinitis pigmentosa 44 28.8 CNGA3 CNGB3 RDH12
15 fundus dystrophy 27.9 CNGA3 CNGB3 IMPG2 RDH12 VPS13B
16 hypertensive heart disease 12.5
17 aland island eye disease 12.4
18 rheumatic heart disease 12.4
19 fish-eye disease 12.4
20 muscle eye brain disease 12.4
21 dry eye syndrome 12.3
22 cat eye syndrome 12.3
23 coronary heart disease 5 12.3
24 critical congenital heart disease 12.3
25 coronary heart disease 7 12.3
26 coronary heart disease 6 12.3
27 testicular anomalies with or without congenital heart disease 12.3
28 microtia with nasolacrimal duct imperforation and eye coloboma 12.2
29 bornholm eye disease 12.2
30 kyphoscoliotic heart disease 12.2
31 coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies syndrome 12.2
32 coronary heart disease 2 12.2
33 eye carcinoma in situ 12.2
34 chronic pulmonary heart disease 12.2
35 hydrocephalus, congenital, 2, with or without brain or eye anomalies 12.1
36 skin/hair/eye pigmentation, variation in, 3 12.1
37 skin/hair/eye pigmentation, variation in, 1 12.1
38 autoimmune disease of eyes, ear, nose and throat 12.1
39 skin/hair/eye pigmentation, variation in, 8 12.1
40 polyvalvular heart disease syndrome 12.1
41 congenital cystic eye 12.1
42 shipyard eye 12.1
43 blind hypotensive eye 12.1
44 skin/hair/eye pigmentation, variation in, 9 12.1
45 eye accommodation disease 12.1
46 eye degenerative disease 12.1
47 coloboma of eye lens 12.1
48 coronary heart disease 4 12.0
49 craniostenosis, sagittal, with congenital heart disease, mental deficiency, and mandibular ankylosis 12.0
50 coronary heart disease 3 12.0

Graphical network of the top 20 diseases related to Rere-Related Disorders:



Diseases related to Rere-Related Disorders

Symptoms & Phenotypes for Rere-Related Disorders

MGI Mouse Phenotypes related to Rere-Related Disorders:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 ABCC6 CNGA3 CNGB3 RDH12

Drugs & Therapeutics for Rere-Related Disorders

Drugs for Rere-Related Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dobutamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34368-04-2 36811
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-31-9 3440
4
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68-04-2
5
Digoxin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 20830-75-5 30322 2724385
6
Metolazone Approved Phase 4,Phase 3,Phase 1,Not Applicable 17560-51-9 4170
7
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
8
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-01-7, 1952-01-7 5833
9
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72956-09-3 2585
10
Verapamil Approved Phase 4,Phase 3,Not Applicable 52-53-9 2520
11
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 114798-26-4 3961
12
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83915-83-7, 76547-98-3 5362119
13
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
14
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
15
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
16
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
18
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-78-2 2244
19
Budesonide Approved Phase 4,Phase 3 51333-22-3 63006 5281004
20
Ipratropium Approved Phase 4,Phase 3 60205-81-4, 22254-24-6 43232 657309
21
Fluticasone Approved, Experimental Phase 4,Phase 3 90566-53-3 62924
22
Terbutaline Approved Phase 4,Not Applicable 23031-25-6 5403
23
Enalaprilat Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 76420-72-9 6917719
24
Enalapril Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 75847-73-3 5362032 40466924
25
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 37350-58-6, 51384-51-1 4171
26
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
27
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 104987-11-3 445643 439492 6473866
28
Saxagliptin Approved Phase 4,Phase 3 361442-04-8 11243969
29
Eplerenone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107724-20-9 150310 443872
30
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1 145040-37-5 2540
31
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
32
Captopril Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 62571-86-2 44093
33
Bisoprolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 66722-44-9 2405
34
Nebivolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 118457-14-0, 99200-09-6, 152520-56-4 71301
35
Tirofiban Approved Phase 4,Not Applicable 144494-65-5 60947
36
Tenecteplase Approved Phase 4,Phase 3,Phase 2,Not Applicable 191588-94-0
37
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
38
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-24-7, 144689-63-4 130881 158781
39
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
40
Pentoxifylline Approved, Investigational Phase 4,Not Applicable 6493-05-6 4740
41
Telmisartan Approved, Investigational Phase 4,Phase 2,Phase 3 144701-48-4 65999
42
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
43
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
44
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
45
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
46
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 171596-29-5 110635
47
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
48
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
49
Gliclazide Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 21187-98-4 3475
50
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488

Interventional clinical trials:

(show top 50) (show all 6562)
# Name Status NCT ID Phase Drugs
1 Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
2 Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline
3 Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
4 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
5 PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing Unknown status NCT00409916 Phase 4
6 Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
7 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
8 Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Unknown status NCT00541268 Phase 4
9 Inspiratory Muscle Training Effectiveness in Sympathetic Activity and Functional Capacity in Patients With Heart Failure Unknown status NCT02600000 Phase 4
10 Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
11 Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
12 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
13 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4 Levosimendan in addition to standard therapy;spironolactone, beta-blockers,ecc
14 Improvement of Patients With Chronic Heart Failure Using NT-proBNP Unknown status NCT00601679 Phase 4
15 A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL) Unknown status NCT00247000 Phase 4
16 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
17 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure Unknown status NCT01156207 Phase 4 Aliskiren
18 Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
19 THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
20 Therapy With Verapamil or Carvedilol in Chronic Heart Failure Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
21 Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
22 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
23 Remission From Stage D Heart Failure Unknown status NCT01774656 Phase 4 Pharmacological Treatment
24 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
25 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
26 Danish ICD Study in Patients With Dilated Cardiomyopathy Unknown status NCT00542945 Phase 4
27 Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication Unknown status NCT01415024 Phase 4
28 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
29 Body Composition Measurements in Chronic Heart Failure Unknown status NCT02686866 Phase 4
30 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
31 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. Unknown status NCT02963597 Phase 4
32 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
33 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
34 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
35 Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial Unknown status NCT02454439 Phase 4
36 Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
37 Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human Unknown status NCT01069042 Phase 4 Enalapril
38 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
39 Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
40 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Unknown status NCT01503671 Phase 4 Atorvastatin
41 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
42 Once-a-day Tacrolimus Conversion Study: The OneTAC Trial Unknown status NCT02545972 Phase 4 tacrolimus extended release
43 Saxagliptin and Cardiac Structure and Function Unknown status NCT02481479 Phase 4 Saxagliptin;Saxagliptin;saxagliptin
44 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
45 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
46 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function Unknown status NCT02509754 Phase 4
47 Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Unknown status NCT02200822 Phase 4 beta blockers;RAAS blockers
48 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
49 Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity Unknown status NCT00326690 Phase 4
50 Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin

Search NIH Clinical Center for Rere-Related Disorders

Genetic Tests for Rere-Related Disorders

Genetic tests related to Rere-Related Disorders:

# Genetic test Affiliating Genes
1 Abnormality of the Eye 30

Anatomical Context for Rere-Related Disorders

MalaCards organs/tissues related to Rere-Related Disorders:

42
Heart, Kidney, Testes, Brain, Endothelial, Bone, Skeletal Muscle

Publications for Rere-Related Disorders

Articles related to Rere-Related Disorders:

(show top 50) (show all 13849)
# Title Authors Year
1
Predictive value of blood urea nitrogen/creatinine ratio in the long-term prognosis of patients with acute myocardial infarction complicated with acute heart failure. ( 30882678 )
2019
2
Re: Association of the Hospital Readmissions Reduction Program with Mortality among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. ( 30888900 )
2019
3
Increased Serum CA125 and Brain-Derived Neurotrophic Factor (BDNF) Levels on Acute Myocardial Infarction: A Predictor for Acute Heart Failure. ( 30706901 )
2019
4
Readmission and mortality in patients ≥70 years with acute myocardial infarction or heart failure in the Netherlands: a retrospective cohort study of incidences and changes in risk factors over time. ( 30715672 )
2019
5
Serum Circulating miR-150 is a Predictor of Post-Acute Myocardial Infarction Heart Failure. ( 30745540 )
2019
6
Relationship Between Patient-Reported Hospital Experience and 30-Day Mortality and Readmission Rates for Acute Myocardial Infarction, Heart Failure, and Pneumonia. ( 30746641 )
2019
7
Understanding the role of echocardiography in remodeling after acute myocardial infarction and development of heart failure with preserved ejection fraction. ( 30779834 )
2019
8
Ischemic heart failure as a complication of incident acute myocardial infarction: Timing and time trends: A national analysis including 78,814 Danish patients during 2000-2009. ( 30813840 )
2019
9
Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. ( 30578576 )
2019
10
Gender disparities among hospitalised patients with acute myocardial infarction, acute decompensated heart failure or pneumonia: retrospective cohort study. ( 30670508 )
2019
11
Implementation of a Cardiac Transitions of Care Pilot Program: A Prospective Study of Inpatient and Outpatient Clinical Pharmacy Services for Patients With Heart Failure Exacerbation or Acute Myocardial Infarction. ( 29183253 )
2019
12
Activin type II receptor signaling in cardiac aging and heart failure. ( 30842316 )
2019
13
Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio, leading to inflamed milieu in acute heart failure. ( 30768364 )
2019
14
Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. ( 30753432 )
2019
15
Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. ( 30649240 )
2019
16
Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure. ( 30718069 )
2019
17
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. ( 30833839 )
2019
18
Does heart failure-specific health status identify patients with bothersome symptoms, depression, anxiety and/or poorer spiritual well-being? ( 30649237 )
2019
19
Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. ( 30765282 )
2019
20
High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia. ( 30790397 )
2019
21
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. ( 30792887 )
2019
22
Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. ( 30413926 )
2019
23
Medicaid Expansion and Mechanical Ventilation in Asthma, Chronic Obstructive Pulmonary Disease, and Heart Failure. ( 30811951 )
2019
24
Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis. ( 30314929 )
2019
25
A 79-year-old woman with atrial fibrillation and new onset of heart failure. ( 30903653 )
2019
26
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. ( 30908512 )
2019
27
Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. ( 30910388 )
2019
28
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. ( 30912456 )
2019
29
Exchange-protein activated by cAMP (EPAC) regulates L-type calcium channel in atrial fibrillation of heart failure model. ( 30915767 )
2019
30
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. ( 30871349 )
2019
31
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model. ( 30874892 )
2019
32
Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). ( 30876658 )
2019
33
Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. ( 30887281 )
2019
34
Procedural Outcomes of Patients With Heart Failure Undergoing Catheter Ablation of Atrial Fibrillation. ( 30893071 )
2019
35
Managements and Outcomes of Hospitalized Heart Failure Patients with Paroxysmal vs. Nonparoxysmal Atrial Fibrillation in Taiwan. ( 30893259 )
2019
36
Case of a patient with heart failure, dilated cardiomyopathy, and atrial fibrillation treated with sacubitril/valsartan. ( 30895821 )
2019
37
Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. ( 30896056 )
2019
38
What Have We Learned From Randomized Controlled Trials of Catheter Ablation for Atrial Fibrillation in Patients With Chronic Heart Failure? ( 30897965 )
2019
39
Relationship between the CHA2DS2VASc score and the occurrence of atrial fibrillation in patients hospitalised due to heart failure. ( 30835325 )
2019
40
Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. ( 30838721 )
2019
41
Catheter Ablation for Atrial Fibrillation in Heart Failure: Ready for Mainstream Adoption, or Is More Evidence Needed? ( 30846417 )
2019
42
Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure? ( 30847508 )
2019
43
Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. ( 30788620 )
2019
44
Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control. ( 30790104 )
2019
45
Association between atrial fibrillation and right-sided manifestations of congestive heart failure in dogs with degenerative mitral valve disease or dilated cardiomyopathy. ( 30797441 )
2019
46
The impact of catheter ablation for atrial fibrillation in heart failure. ( 30805042 )
2019
47
Atrial fibrillation among adults with heart failure in sub-Saharan Africa - prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol. ( 30808667 )
2019
48
Burden of Implanted-Device-Detected Atrial High-Rate Episode Is Associated With Future Heart Failure Events - Clinical Significance of Asymptomatic Atrial Fibrillation in Patients With Implantable Cardiac Electronic Devices. ( 30814400 )
2019
49
Ethnicity, heart failure, atrial fibrillation and diabetes: collider bias. ( 30728157 )
2019
50
Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. ( 30661038 )
2019

Variations for Rere-Related Disorders

ClinVar genetic disease variations for Rere-Related Disorders:

6 (show top 50) (show all 54)
# Gene Variation Type Significance SNP ID Assembly Location
1 CACNA2D4 NM_172364.4(CACNA2D4): c.1882C> T (p.Arg628Ter) single nucleotide variant Uncertain significance rs200098356 GRCh37 Chromosome 12, 1969369: 1969369
2 CACNA2D4 NM_172364.4(CACNA2D4): c.1882C> T (p.Arg628Ter) single nucleotide variant Uncertain significance rs200098356 GRCh38 Chromosome 12, 1860203: 1860203
3 VPS13B NM_017890.4(VPS13B): c.6370_6371delAT (p.Met2124Valfs) deletion Conflicting interpretations of pathogenicity rs748404277 GRCh37 Chromosome 8, 100712001: 100712002
4 VPS13B NM_017890.4(VPS13B): c.6370_6371delAT (p.Met2124Valfs) deletion Conflicting interpretations of pathogenicity rs748404277 GRCh38 Chromosome 8, 99699773: 99699774
5 RDH12 NM_152443.2(RDH12): c.806_810delCCCTG (p.Ala269Glyfs) deletion Pathogenic rs386834261 GRCh37 Chromosome 14, 68196055: 68196059
6 RDH12 NM_152443.2(RDH12): c.806_810delCCCTG (p.Ala269Glyfs) deletion Pathogenic rs386834261 GRCh38 Chromosome 14, 67729338: 67729342
7 CNGB3 NM_019098.4(CNGB3): c.1148delC (p.Thr383Ilefs) deletion Conflicting interpretations of pathogenicity rs397515360 GRCh37 Chromosome 8, 87656009: 87656009
8 CNGB3 NM_019098.4(CNGB3): c.1148delC (p.Thr383Ilefs) deletion Conflicting interpretations of pathogenicity rs397515360 GRCh38 Chromosome 8, 86643781: 86643781
9 ABCC6 NM_001171.5(ABCC6): c.3389C> T (p.Thr1130Met) single nucleotide variant Pathogenic/Likely pathogenic rs63750459 GRCh37 Chromosome 16, 16256967: 16256967
10 ABCC6 NM_001171.5(ABCC6): c.3389C> T (p.Thr1130Met) single nucleotide variant Pathogenic/Likely pathogenic rs63750459 GRCh38 Chromosome 16, 16163110: 16163110
11 VPS13B NM_017890.4(VPS13B): c.2591C> A (p.Ser864Ter) single nucleotide variant Pathogenic rs140936527 GRCh37 Chromosome 8, 100286501: 100286501
12 VPS13B NM_017890.4(VPS13B): c.2591C> A (p.Ser864Ter) single nucleotide variant Pathogenic rs140936527 GRCh38 Chromosome 8, 99274273: 99274273
13 VPS13B NM_017890.4(VPS13B): c.3628G> T (p.Asp1210Tyr) single nucleotide variant Uncertain significance rs145417421 GRCh37 Chromosome 8, 100479824: 100479824
14 VPS13B NM_017890.4(VPS13B): c.3628G> T (p.Asp1210Tyr) single nucleotide variant Uncertain significance rs145417421 GRCh38 Chromosome 8, 99467596: 99467596
15 CNGB3 NM_019098.4(CNGB3): c.1208G> A (p.Arg403Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs147876778 GRCh37 Chromosome 8, 87645092: 87645092
16 CNGB3 NM_019098.4(CNGB3): c.1208G> A (p.Arg403Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs147876778 GRCh38 Chromosome 8, 86632864: 86632864
17 CNGA3 NM_001298.2(CNGA3): c.1688G> A (p.Arg563His) single nucleotide variant Pathogenic rs552069173 GRCh37 Chromosome 2, 99013321: 99013321
18 CNGA3 NM_001298.2(CNGA3): c.1688G> A (p.Arg563His) single nucleotide variant Pathogenic rs552069173 GRCh38 Chromosome 2, 98396858: 98396858
19 46;XX;inv(6)(p11.1q21)dn inversion Uncertain significance
20 CNGB3 NM_019098.4(CNGB3): c.1285delT (p.Ser429Leufs) deletion Pathogenic/Likely pathogenic rs776896038 GRCh37 Chromosome 8, 87645015: 87645015
21 CNGB3 NM_019098.4(CNGB3): c.1285delT (p.Ser429Leufs) deletion Pathogenic/Likely pathogenic rs776896038 GRCh38 Chromosome 8, 86632787: 86632787
22 ABCC6 NM_001171.5(ABCC6): c.4104delC (p.Asp1368Glufs) deletion Pathogenic rs72664237 GRCh38 Chromosome 16, 16154732: 16154732
23 ABCC6 NM_001171.5(ABCC6): c.4104delC (p.Asp1368Glufs) deletion Pathogenic rs72664237 GRCh37 Chromosome 16, 16248589: 16248589
24 GNAT2 NM_005272.3(GNAT2): c.906C> A (p.Tyr302Ter) single nucleotide variant Likely pathogenic rs1553226355 GRCh37 Chromosome 1, 110146135: 110146135
25 GNAT2 NM_005272.3(GNAT2): c.906C> A (p.Tyr302Ter) single nucleotide variant Likely pathogenic rs1553226355 GRCh38 Chromosome 1, 109603513: 109603513
26 CNGA3 NM_001298.2(CNGA3): c.107_110delACTC (p.His36Argfs) deletion Likely pathogenic rs749036398 GRCh37 Chromosome 2, 98994155: 98994158
27 CNGA3 NM_001298.2(CNGA3): c.107_110delACTC (p.His36Argfs) deletion Likely pathogenic rs749036398 GRCh38 Chromosome 2, 98377692: 98377695
28 IMPG2 NM_016247.3(IMPG2): c.1680T> A (p.Tyr560Ter) single nucleotide variant Pathogenic rs758291149 GRCh37 Chromosome 3, 100963495: 100963495
29 IMPG2 NM_016247.3(IMPG2): c.1680T> A (p.Tyr560Ter) single nucleotide variant Pathogenic rs758291149 GRCh38 Chromosome 3, 101244651: 101244651
30 CNGB3 NM_019098.4(CNGB3): c.1810C> T (p.Arg604Ter) single nucleotide variant Likely pathogenic rs200805087 GRCh38 Chromosome 8, 86579224: 86579224
31 CNGB3 NM_019098.4(CNGB3): c.1810C> T (p.Arg604Ter) single nucleotide variant Likely pathogenic rs200805087 GRCh37 Chromosome 8, 87591452: 87591452
32 RBP4 NM_006744.3(RBP4): c.248+1G> A single nucleotide variant Likely pathogenic rs111785373 GRCh38 Chromosome 10, 93600666: 93600666
33 RBP4 NM_006744.3(RBP4): c.248+1G> A single nucleotide variant Likely pathogenic rs111785373 GRCh37 Chromosome 10, 95360423: 95360423
34 TYR NM_000372.4(TYR): c.1037G> T (p.Gly346Val) single nucleotide variant Likely pathogenic rs773970123 GRCh38 Chromosome 11, 89227823: 89227823
35 TYR NM_000372.4(TYR): c.1037G> T (p.Gly346Val) single nucleotide variant Likely pathogenic rs773970123 GRCh37 Chromosome 11, 88960991: 88960991
36 RPGRIP1 NM_020366.3(RPGRIP1): c.2398G> A (p.Glu800Lys) single nucleotide variant Likely pathogenic rs565837539 GRCh37 Chromosome 14, 21794020: 21794020
37 RPGRIP1 NM_020366.3(RPGRIP1): c.2398G> A (p.Glu800Lys) single nucleotide variant Likely pathogenic rs565837539 GRCh38 Chromosome 14, 21325861: 21325861
38 NR2E3 NM_016346.3(NR2E3): c.305C> A (p.Ala102Asp) single nucleotide variant Likely pathogenic rs772881093 GRCh38 Chromosome 15, 71811825: 71811825
39 NR2E3 NM_016346.3(NR2E3): c.305C> A (p.Ala102Asp) single nucleotide variant Likely pathogenic rs772881093 GRCh37 Chromosome 15, 72104165: 72104165
40 NYX NM_022567.2(NYX): c.936C> G (p.Asn312Lys) single nucleotide variant Likely pathogenic rs1555967263 GRCh38 Chromosome X, 41474389: 41474389
41 NYX NM_022567.2(NYX): c.936C> G (p.Asn312Lys) single nucleotide variant Likely pathogenic rs1555967263 GRCh37 Chromosome X, 41333642: 41333642
42 RP2 NM_006915.2(RP2): c.43delT (p.Ser15Argfs) deletion Likely pathogenic rs1556313474 GRCh37 Chromosome X, 46696578: 46696578
43 RP2 NM_006915.2(RP2): c.43delT (p.Ser15Argfs) deletion Likely pathogenic rs1556313474 GRCh38 Chromosome X, 46837143: 46837143
44 CACNA1F NM_005183.3(CACNA1F): c.3628C> T (p.Gln1210Ter) single nucleotide variant Likely pathogenic rs782362725 GRCh37 Chromosome X, 49071548: 49071548
45 CACNA1F NM_005183.3(CACNA1F): c.3628C> T (p.Gln1210Ter) single nucleotide variant Likely pathogenic rs782362725 GRCh38 Chromosome X, 49215088: 49215088
46 CHM NM_000390.3(CHM): c.315-1536A> G single nucleotide variant Likely pathogenic rs1555955061 GRCh37 Chromosome X, 85220593: 85220593
47 CHM NM_000390.3(CHM): c.315-1536A> G single nucleotide variant Likely pathogenic rs1555955061 GRCh38 Chromosome X, 85965588: 85965588
48 AHI1 NC_000006.12: g.135437869_135441094del3226 deletion Likely pathogenic GRCh37 Chromosome 6, 135759007: 135762232
49 AHI1 NC_000006.12: g.135437869_135441094del3226 deletion Likely pathogenic GRCh38 Chromosome 6, 135437869: 135441094
50 TRPM6 NC_000009.12: g.74773801_74783660del9860 deletion Likely pathogenic GRCh37 Chromosome 9, 77388717: 77398576

Expression for Rere-Related Disorders

Search GEO for disease gene expression data for Rere-Related Disorders.

Pathways for Rere-Related Disorders

GO Terms for Rere-Related Disorders

Cellular components related to Rere-Related Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter complex GO:1902495 8.62 CNGA3 CNGB3

Biological processes related to Rere-Related Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.26 ABCC6 CNGA3 CNGB3 RDH12
2 cation transport GO:0006812 9.16 CNGA3 CNGB3
3 visual perception GO:0007601 9.02 ABCC6 CNGA3 CNGB3 IMPG2 RDH12

Molecular functions related to Rere-Related Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cGMP binding GO:0030553 9.16 CNGA3 CNGB3
2 intracellular cAMP-activated cation channel activity GO:0005222 8.96 CNGA3 CNGB3
3 intracellular cGMP-activated cation channel activity GO:0005223 8.62 CNGA3 CNGB3

Sources for Rere-Related Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....